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Concise Communication

Impact of antibiotic heterogeneity by periodic antibiotic monitoring
and supervision strategy at two units with different prevalences
of multidrug-resistant organisms
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1
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Abstract
In an intensive care unit, antibiotic heterogeneity led to an increase in antibiotic heterogeneity index (P = .002) and a reduction in carbapenem-resistance Enterobacteriaceae incidence (P = .04). In a general medicine unit with low prevalence of multidrug-resistant organisms,
antibiotic heterogeneity index and incidence of multidrug-resistant organisms did not improve.
(Received 8 March 2021; accepted 14 May 2021)

Antibiotic heterogeneity is the concept of using a variety of
antibiotics for specific clinical indications to improve hospital ecology, resulting in limiting the emergence of multidrug-resistant
organisms (MDROs).1 One of the antibiotic heterogeneity strategies is called Periodic Antibiotic Monitoring and Supervision
(PAMS). This strategy has been recommended by Asian experts
despite limited evidence.2 Using a hospital-wide PAMS strategy,
Takesue et al3 changed the recommended classes of antibiotics
for various conditions every 3 months according to the calculated
antibiotic heterogeneity index. They noted a decrease in the
overall incidence of multidrug-resistant gram-negative bacilli
(MDR-GNB).3 Another study reported that implementation
of PAMS in a noncritical-care surgical unit did not reduce
MDR-GNB.4 Because data on PAMS interventions in medical
units are limited, we performed a quasi-experimental study
to evaluate the role of PAMS in 2 different medical units with
different MDR-GNB prevalences.
Methods
From December 1, 2018, through November 30, 2020, at
Thammasat University Hospital (TUH), we performed a quasiexperimental study to evaluate the role of PAMS in an intensive
care unit (ICU) with a high incidence of MDR-GNB and in a
general medicine unit with a low incidence of MDR-GNB. All
patients in these units were prospectively followed for the primary
and secondary outcomes. The study periods consisted of 1 year
before the implementation of PAMS (December 1, 2018, through
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November 30, 2019) and 1 year after the implementation of
PAMS (December 1, 2019, through November 30, 2020). PAMS
was conducted by a multidisciplinary antibiotic stewardship
program (ASP) team.
During the entire study period, the antibiotic heterogeneity
index, defined daily doses (DDD), and antibiotic usage density
were prospectively followed by a clinical pharmacist. The antibiotic
usage density was defined as the cumulative use of the specific
antibiotics class in DDD divided by the cumulative use of the
overall antibiotics classes. During the entire study period, the
infection prevention interventions to reduce MDR-GNB included
hand hygiene, contact precautions, environmental cleaning and
disinfection, and weekly admission active surveillance cultures
for CRE. The incidence of MDR-GNB was prospectively monitored by the infection prevention team. The prevalences of
MDROs (isolates per 1,000 patient days) in the ICU versus the
general medical unit were as follows: MDR Pseudomonas aeruginosa (0.29 vs 0.11), MDR Acinetobactor baumannii (3.45 vs 0.26),
carbapenem-resistant Enterobacteriaceae (CRE; 2.70 vs 0.08),
and extended-spectrum β-lactamase (ESBL)–producing microorganisms (2.94 vs 0). The primary outcome was improvement
in the antibiotic heterogeneity index. The secondary outcomes
were MDR-GNB incidence, excluding community-onset ESBLproducing microorganisms,5 antibiotics consumption (DDD per
1,000 patient days), 30-day mortality, and length of hospital stay.
During period 2, a clinical pharmacist calculated the monthly
percentage of antibiotic usage density for each antibiotics class.
The ASP team then regularly contacted the treating physicians
in each unit to recommend the antibiotics that had low antibiotic
usage density for use in appropriate indications, or to recommend
the antibiotics with low antibiotic usage density to replace the current antibiotics regimen. However, the final antibiotics decisions
were made by the treating physicians.
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Table 1. Characteristics of the Study Population
Intensive Care Unita

General Medicine Unita

Variables

Total
(N = 658)

Period 1
(N = 333)

Period 2
(N = 325)

P Value

Total
(N = 1,997)

Period 1
(N = 1,057)

Period 2
(N = 940)

P Value

Age, mean y ±SD

60 ± 19.6

58.3 ± 20.2

61.7 ± 18.9

.03

62.6 ± 21.5

63 ± 24.0

62 ± 18.2

.30

Sex, female

273 (41.5)

152 (45.7)

121 (37.2)

.03

1671 (83.7)

900 (85.2)

771 (82)

.06

349 (53)

173 (52)

176 (54.2)

.57

1124 (56.3)

614 (58.1)

510 (54.3)

.09

216 (32.8)

100 (30)

116 (35.7)

.12

726 (36.4)

384 (36.3)

342 (36.4)

.98

Underlying diseases
Hypertension
Diabetes
Heart diseases

167 (25.4)

83 (24.9)

84 (25.9)

.79

750 (37.6)

386 (36.6)

364 (38.7)

.31

Otherb

428 (65.1)

219 (65.8)

209 (64.3)

.70

1,303 (65.3)

687 (65)

616 (65.5)

.80

307 (46.7)

155 (46.6)

152 (46.8)

.95

189 (9.5)

105 (9.9)

84 (8.9)

.45

Source of infection
Respiratory tract
Urinary tract

70 (10.6)

44 (13.2)

26 (8)

.03

216 (10.8)

126 (11.9)

90 (9.6)

.09

Bacteremia

81 (12.3)

45 (13.5)

36 (11.1)

.34

75 (3.8)

41 (3.9)

34 (3.6)

.76

c

129 (19.6)

75 (22.5)

54 (16.6)

.06

192 (9.61)

107 (10.1)

85 (9)

.41

Length of hospital stay,
mean d ± SD

9.7 ± 13.0

9.6 ± 11.7

9.7 ± 14.3

.97

6.1 ± 5.5

6.2 ± 5.4

6 ± 5.7

.47

30-day mortality

158 (24)

77 (23.1)

81 (24.9)

.59

29 (1.5)

18 (1.7)

11 (1.2)

.32

Total
(Dec 2018–
Nov 2020)

Period 1
(Dec 2018–
Nov 2019)

P Value

Total
(Dec 2018–
Nov 2020)

Other

Intensive Care Unit

Antibiotics consumption
Overall antibiotics

958.2 ± 220

991 ± 511.4

Period 2
(Dec 2019–
Nov 2020)
925.5 ± 220

General Medicine Unit

.69

327.5 ± 86.7

Period 1
(Dec 2018–
Nov 2019)

Period 2
(Dec 2019–
Nov 2020)

P Value

344.2 ± 81.3

310.7 ± 92.1

.36

Carbapenems

303.8 ± 184.4

336.6 ± 228.5

270.9 ± 128.5

.40

53.3 ± 41

51.4 ± 39.3

55.1 ± 44.3

.83

Fluoroquinolones

131.9 ± 118.7

105.2 ± 90.6

158.7 ± 140.2

.28

25.7 ± 17.9

25.7 ± 13.7

25.7 ± 22

.99

258 ± 61.5

.09

119.1 ± 58.5

142.7 ± 47.5

95.6 ± 60.7

.05

160.3 ± 73.3

.08

127.5 ± 60.1

120.6 ± 61.4

134.3 ± 60.6

.59

BLBIs
Third- and fourth-generation cephalosporins

290 ± 122.5
133.9 ± 73.3

332 ± 154.1
107.5 ± 66.9

Note. DDD, defined daily dose; SD, standard deviation, BLBIs, β-lactam β-lactamase inhibitors.
a
Data are no. (%) unless otherwise indicated. Antibiotic consumptions are represented as DDD/1,000 patient days (mean ± SD).
b
Other underlying diseases were malignancies, kidney diseases, lung diseases, liver diseases and neurological diseases.
c
Other sources of infection were bone and joint, skin and soft tissue, central nervous system, intra-abdomen and unidentified sources.

Antibiotic usage density was classified into 3 categories based
on a previous study.3 Recommendations for antibiotics switching
are summarized in Supplementary Material 1 (online). A modified
version of the Peterson index was used to calculate the antibiotic
heterogeneity index (Supplementary Material 1 online).6 The antibiotic heterogeneity index was used as a surrogate marker for
achievement of antibiotic heterogeneity. The thresholds for the
antibiotic heterogeneity index were chosen to achieve a target value
of >0.85.3 Data collected included patient demographics, primary
outcome, and secondary outcomes. This study was approved by the
institutional review board.
All analyses were performed using Stata version 16 software
(StataCorp, College Station, TX). We used the χ2 test to compare
categorical variables. Independent t tests were used for continuous
data. Time-series analyses were performed to evaluate the antibiotic heterogeneity index and the incidences of MDR-GNB. All P
values were 2-tailed; P < .05 was considered statistically significant.
Results
In total, we enrolled 1,390 patients in the preimplementation
period (period 1) and 1,265 patients in the postimplementation

period (period 2). During period 1, there were 2,764 total patient
days in the ICU and 5,565 total patient days in the general medicine
unit. In period 2, there were 2,802 total patient days in the ICU and
4,756 total patient days in the general medicine unit. The mean age
for all study participants was 62 years (SD, ±21.04). The most
common underlying diseases were hypertension (55.5%) and diabetes mellitus (35.5%). Demographics and baseline characteristics
of the study populations were compared during both periods
(Table 1).
Using time series analysis, we detected a significant improvement in the antibiotic heterogeneity index in the ICU (coefficient,
0.015; P = .002) in period 2 compared to period 1, and the antibiotic heterogeneity index in the general medicine unit improved
(coefficient, 0.020; P = .06). In the ICU, a decreasing trend in
the incidence of the overall MDR-GNB occurred in period 2
(coefficient, −0.585; P = .11). Notably, we detected a significant
reduction in CRE incidence (coefficient, −0.279; P = .04) as well
as a reductions in the incidences of other MDR-GNB (Fig. 1).
Compared to period 1, in the ICU, the overall DDD (P = .69),
length of stay (P = .97), and 30-day mortality (P = .59) did not
improve significantly in period 2 (Table 1). In the general medicine
unit, the MDR-GNB incidence decreased (coefficient, −0.377;
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Fig. 1. Antibiotic heterogeneity index, incidence of overall multidrug-resistant organisms (MDROs), and incidence of specific MDROs in both units.

P = .06). However, the overall DDD (P = .36), length of stay
(P = .47) and 30-day mortality (P = .32) did not significantly
decrease (Table 1).
Discussion
Our study yielded some notable findings. First, PAMS was implemented successfully in the ICU, which had a high prevalence
of MDROs, and it led to a significant reduction in CRE incidence.

Second, due to the low prevalence of MDROs in the general
medicine unit, PAMS did not lead to significant reductions in overall MDR-GNB incidence. The key to improvement in the antibiotic
heterogeneity index may be a high baseline prevalence of MDROs
and a variety of antibiotics options, whereas improvement of
MDR-GNB incidence may require a longer PAMS period.
In our study, in the ICU, consumption of carbapenems and
β-lactam β-lactamase inhibitors (BLBIs) decreased. These findings
may explain the overall decreases in MDR-GNB and a significant
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reduction in the CRE incidence in the ICU. We observed decreases
in BLBI consumption in both units, which correlated with the
reduction of MDR-A. baumannii in both units.7 Compared with
previous studies,3,4 our findings suggest that antibiotic heterogeneity index implementation may be successful in a medical
ICU where the prevalence of MDROs is high and that such a strategy may not be practical in a general medicine unit with a low
MDRO prevalence.
Our study has several limitations. First, this study was
performed in a university hospital, where the choices of antibiotics were limited by patient insurance. Thus, our findings may
not be applicable to hospitals that have a wider antibiotics
choices. Second, the sample size and duration of follow-up in
the ICU may not have been sufficient to reveal a significant
reduction in antibiotics consumption and specific MDR-GNB
incidences. Third, we were unable to evaluate the trend for
ESBL-producing microorganisms in the general medicine unit
because most cases were community-onset ESBLs. Fourth, time
series analysis has limitations because it lacks a comparative
arm. Finally, during period 2, the number of patients in the
general medicine unit decreased by 11% due to the COVID19 pandemic.
In conclusion, PAMS can be implemented successfully in
a medical ICU with a high MDRO prevalence and may lead to a
reduction in the incidence of MDR-GNB and CRE. Successful
implementation of PAMS may require a wide variety of antibiotics
choices, baseline prevalence of MDROs, and a long follow-up
durations. Further studies to evaluate the role of PAMS in specific
populations (eg, the neutropenic population and the pediatric
ICU) are needed.
Supplementary material. To view supplementary material for this article,
please visit https://doi.org/10.1017/ice.2021.231
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